Effects of Ketosis on Muscle Kinetics and Signaling During Critical Illness.

Phase 2

Not yet recruiting

• Conditions: Intensive Care Unit Acquired Weakness; Critical Illness
• Interventions: Dietary Supplement: KetoneAid KE4 Pro Monoester; Dietary Supplement: Maltodextrin and fat-based placebo

• Registration Number: NCT05074862
• Lead Sponsor: Aarhus University Hospital

Brief Summary

Background:

Patients with critical illness in the intensive care unit (ICU) experience marked skeletal muscle weakness, muscle atrophy and disability in physical function, commonly termed ICU-acquired weakness (ICU-AW). The pathophysiology of ICU-AW is complex, but a key feature of skeletal muscle wasting is disturbed protein metabolism reflected in both increased rate of muscle protein degradation and reduced synthesis. Treatment with 3-OHB seems a promising new anticatabolic treatment in patients with critical illness, preventing ICU-AW. To date, no data exist on the clinical and functional effects of ketone body modulation in patients with critical illness.

Objective:

The aim to investigate the effect of exogenous 3-OHB administration on muscle protein kinetics and lipolysis in patients with critical illness, aiming towards preventing ICU-AW.

Design:

A randomized double-blind isocaloric placebo-controlled cross-over study in 10 mechanically ventilated patients with critical illness in the ICU.

Methods:

Evaluation of whole-body and focal leg protein kinetics using labeled phenylalanine and tyrosine tracers. Assessment of free fatty acid (FFA) turnover using a labeled palmitate tracer. Femoral arterial blood flow (assessed with pulsed-wave Doppler ultrasound) is evaluated once per study period. Blood- and urinary samples are collected routinely throughout the study day. Whenever feasible, muscle and fat biopsies will be taken for analysis of protein and adipocyte metabolic signaling and mitochondrial function.

Perspectives: This investigation may grant essential knowledge on ketosis in critical illness. This may lead to larger clinical trials, and hopefully a new and better treatment strategy aimed at preserving muscle mass and function during and improving recovery after critical illness.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-09-17
• Study First Submitted QC: 2021-09-29
• Study First Posted: 2021-10-12
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-02
• Last Update Posted: 2022-11-04
• Study Start: 2023-01-01
• Primary Completion: 2023-06-01
• Study Completion: 2023-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Invasive mechanical ventilation via a cuffed endotracheal or tracheotomy tube.
• Expected survival of ICU admission.
• Adults (≥18 years).
• Multi-organ failure (Sequential Organ Failure Assessment Score [SOFA] score ≥2 in 2 or more domains).

Exclusion Criteria

• Moribund or expected withholding treatment within 48 hours as judged by the investigator.
• Palliative goals of care.
• Contraindication for enteral nutrition.
• Pregnancy.
• Known severe musculoskeletal or neurological disability.
• Diabetic ketoacidosis.
• Phenylketonuria.
• BMI ≤17 or deemed malnourished as judged by the investigator.
• BMI >40.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Ketone monoester (3-OHB)	KetoneAid KE4 Pro Monoester	Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 300 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 100 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
Placebo Treatment	Maltodextrin and fat-based placebo	Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.

Primary Outcome Measures

Name	Time	Method
Net leg phenylalanine release	3 hours	As measured by rate of phenylalanine appearance in relation with the rate of disappearance.

Secondary Outcome Measures

Name	Time	Method
Changes in intramyocellular protein metabolic signalling pathways.	3 hours.	The Akt-, mTor-, and ubiquitin-proteasome pathways.
Change in rate of appearance of phenylalanine over the leg.	3 hours.
Change in rate of disappearance of phenylalanine over the leg.	3 hours.
Whole body palmitate flux	3 hours.	As measured by rate of appearance of a palmitate-tracer
Change in arterial pH.	3 hours.
Changes in inflammatory cytokines (IL-1, IL-6, IL-18, TNFa)	3 hours.

Trial Locations

Locations (1)

Aarhus University Hospital; 🇩🇰 Aarhus, Denmark